PIK3CA and Hyperglycemia: Hyperglycemia is a particularly challenging on-target class effect of PI3K inhibitors [17,23], and was the most common all-grade AE reported in patients treated with alpelisib in clinical trials, with a random-effect absolute risk of 59% (95% CI, 0.51–0.66) [22].